Overview Financials News + Filings IR Vault Key Docs Charts Holdings Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Laboratory Products & Services | | | | | 10,035.0 | 7,825.0 | 6,724.0 | 6,372.0 |
| Life Sciences Solutions | 13,532.0 | 15,631.0 | 12,168.0 | 6,856.0 | 6,269.0 | 5,728.0 | 5,317.0 | 4,774.0 |
| Analytical Instruments | 6,624.0 | 6,069.0 | 5,124.0 | 5,522.0 | 5,469.0 | 4,821.0 | 3,668.0 | 3,208.0 |
| Specialty Diagnostics | 4,763.0 | 5,659.0 | 5,343.0 | 3,718.0 | 3,724.0 | 3,486.0 | 3,339.0 | 3,244.0 |
| Other | 19,996.0 | 11,852.0 | 9,583.0 | 9,446.0 | | | | |
| Total revenues [+] | 44,915.0 | 39,211.0 | 32,218.0 | 25,542.0 | 24,358.0 | 20,918.0 | 18,274.0 | 16,965.0 |
| Products | | | | | | | | 14,668.0 |
| Services | | | | | | | | 2,297.0 |
| Revenue growth [+] | 14.5% | 21.7% | 26.1% | 4.9% | 16.4% | 14.5% | 7.7% | 0.4% |
| Laboratory Products & Services | | | | | 28.2% | 16.4% | 5.5% | -3.5% |
| Life Sciences Solutions | -13.4% | 28.5% | 77.5% | 9.4% | 9.4% | 7.7% | 11.4% | 13.8% |
| Analytical Instruments | 9.1% | 18.4% | -7.2% | 1.0% | 13.4% | 31.4% | 14.3% | -1.4% |
| Specialty Diagnostics | -15.8% | 5.9% | 43.7% | -0.2% | 6.8% | 4.4% | 2.9% | -3.0% |
| Other | 2.6% | 29.8% | | | | | | |
| Cost of goods sold [+] | 25,944.0 | 19,573.0 | 16,214.0 | 14,214.0 | 13,501.0 | 11,567.0 | 10,336.0 | 9,209.0 |
| Cost of product sales | | | | | | | | 7,584.0 |
| Cost of services | | | | | | | | 1,625.0 |
| Gross profit | 18,971.0 | 19,638.0 | 16,004.0 | 11,328.0 | 10,857.0 | 9,351.0 | 7,938.0 | 7,756.0 |
| Gross margin | 42.2% | 50.1% | 49.7% | 44.4% | 44.6% | 44.7% | 43.4% | 45.7% |
| Selling, general and administrative | 8,993.0 | 8,007.0 | 6,930.0 | 6,144.0 | 6,057.0 | 5,504.0 | 4,971.0 | 4,612.0 |
| Research and development | 1,471.0 | 1,406.0 | 1,181.0 | 1,003.0 | 967.0 | 887.0 | 754.0 | 692.0 |
| Equity in earnings | -172.0 | -4.0 | -3.0 | | | | | |
| EBITDA [+] | 11,716.0 | 12,813.0 | 10,215.0 | 6,458.0 | 6,100.0 | 4,993.0 | 4,405.0 | 4,140.0 |
| EBITDA growth | -8.6% | 25.4% | 58.2% | 5.9% | 22.2% | 13.3% | 6.4% | 15.3% |
| EBITDA margin | 26.1% | 32.7% | 31.7% | 25.3% | 25.0% | 23.9% | 24.1% | 24.4% |
| Depreciation | 986.0 | 831.0 | 658.0 | 564.0 | 526.0 | 439.0 | 378.0 | 378.0 |
| EBITA | 10,730.0 | 11,982.0 | 9,557.0 | 5,894.0 | 5,574.0 | 4,554.0 | 4,027.0 | 3,762.0 |
| EBITA margin | 23.9% | 30.6% | 29.7% | 23.1% | 22.9% | 21.8% | 22.0% | 22.2% |
| Amortization of intangibles | 2,395.0 | 1,761.0 | 1,667.0 | 1,713.0 | 1,741.0 | 1,594.0 | 1,380.0 | 1,310.0 |
| EBIT [+] | 8,335.0 | 10,221.0 | 7,890.0 | 4,181.0 | 3,833.0 | 2,960.0 | 2,647.0 | 2,452.0 |
| EBIT growth | -18.5% | 29.5% | 88.7% | 9.1% | 29.5% | 11.8% | 8.0% | 28.7% |
| EBIT margin | 18.6% | 26.1% | 24.5% | 16.4% | 15.7% | 14.2% | 14.5% | 14.5% |
| Non-recurring items [+] | 114.0 | 197.0 | 99.0 | -413.0 | 50.0 | | 189.0 | 116.0 |
| Asset impairment | | | | | | | 189.0 | |
| Interest expense, net [+] | 454.0 | 493.0 | 488.0 | 452.0 | 530.0 | 511.0 | -48.0 | -31.0 |
| Interest expense | 726.0 | 536.0 | 553.0 | 676.0 | 667.0 | 592.0 | 469.0 | 415.0 |
| Interest income | 272.0 | 43.0 | 65.0 | 224.0 | 137.0 | 81.0 | 48.0 | 31.0 |
| Other income (expense), net [+] | 68.0 | -690.0 | -73.0 | -70.0 | 9.0 | -20.0 | -13.0 | -16.0 |
| Other | -104.0 | -694.0 | -76.0 | -70.0 | 9.0 | -20.0 | | |
| Pre-tax income | 7,835.0 | 8,841.0 | 7,230.0 | 4,072.0 | 3,262.0 | 2,429.0 | 2,024.0 | 1,936.0 |
| Income taxes | 703.0 | 1,109.0 | 850.0 | 374.0 | 324.0 | 201.0 | -1.0 | -44.0 |
| Tax rate | 9.0% | 12.5% | 11.8% | 9.2% | 9.9% | 8.3% | | |
| Minority interest | 10.0 | 3.0 | 2.0 | 2.0 | | | | |
| Earnings from continuing ops | 6,950.0 | 7,725.0 | 6,375.0 | 3,696.0 | 2,938.0 | 2,228.0 | 2,025.0 | 1,980.0 |
| Earnings from discontinued ops | | | | | | -3.0 | -3.0 | -5.0 |
| Net income | 6,950.0 | 7,725.0 | 6,375.0 | 3,696.0 | 2,938.0 | 2,225.0 | 2,022.0 | 1,975.0 |
| Net margin | 15.5% | 19.7% | 19.8% | 14.5% | 12.1% | 10.6% | 11.1% | 11.6% |
| |
| Basic EPS [+] | $17.73 | $19.61 | $16.10 | $9.24 | $7.31 | $5.64 | $5.13 | $4.96 |
| Growth | -9.6% | 21.8% | 74.2% | 26.4% | 29.6% | 10.0% | 3.3% | 4.2% |
| Diluted EPS [+] | $17.64 | $19.46 | $15.98 | $9.17 | $7.24 | $5.60 | $5.10 | $4.93 |
| Growth | -9.3% | 21.8% | 74.2% | 26.7% | 29.3% | 9.7% | 3.6% | 4.5% |
| |
| Dividends per share [+] | $1.20 | $1.04 | $0.88 | $0.76 | $0.68 | $0.60 | $0.60 | $0.60 |
| Growth | 15.4% | 18.2% | 15.8% | 11.8% | 13.3% | 0.0% | 0.0% | 0.0% |
| |
| Shares outstanding (basic) [+] | 392.0 | 394.0 | 396.0 | 400.0 | 402.0 | 395.0 | 395.0 | 399.0 |
| Growth | -0.5% | -0.5% | -1.0% | -0.5% | 1.8% | 0.0% | -1.0% | 0.2% |
| Shares outstanding (diluted) [+] | 394.0 | 397.0 | 399.0 | 403.0 | 406.0 | 398.0 | 397.0 | 402.0 |
| Growth | -0.8% | -0.5% | -1.0% | -0.7% | 2.0% | 0.3% | -1.2% | -0.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|